Technical Analysis for CORT - Corcept Therapeutics Incorporated
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Historical CORT trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 5.99% | |
MACD Bullish Signal Line Cross | Bullish | 4.28% | |
NR7 | Range Contraction | 4.10% | |
Oversold Stochastic | Weakness | 4.10% | |
Slingshot Bearish | Bearish Swing Setup | 4.05% | |
Bullish Engulfing | Bullish | 4.05% | |
Oversold Stochastic | Weakness | 4.05% | |
NR7 | Range Contraction | 7.18% | |
Down 3 Days in a Row | Weakness | 7.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 3% | about 13 hours ago |
Up 2% | about 16 hours ago |
60 Minute Opening Range Breakout | about 16 hours ago |
20 DMA Resistance | about 17 hours ago |
Up 1% | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/03/2021
Corcept Therapeutics Incorporated Description
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Organ Systems Surgery Diabetes Clinical Research Disorders Endocrine System Glucose Hormones Diabetes Mellitus Depression Psychiatric Disorders Cushing's Syndrome Hyperglycemia Stanford University Cortisol Endogenous Cushing's Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 31.18 |
52 Week Low | 11.91 |
Average Volume | 526,827 |
200-Day Moving Average | 21.39 |
50-Day Moving Average | 24.86 |
20-Day Moving Average | 23.34 |
10-Day Moving Average | 22.85 |
Average True Range | 0.83 |
ADX | 26.13 |
+DI | 20.11 |
-DI | 22.12 |
Chandelier Exit (Long, 3 ATRs ) | 23.22 |
Chandelier Exit (Short, 3 ATRs ) | 24.62 |
Upper Bollinger Band | 24.67 |
Lower Bollinger Band | 22.01 |
Percent B (%b) | 0.7 |
BandWidth | 11.39 |
MACD Line | -0.53 |
MACD Signal Line | -0.67 |
MACD Histogram | 0.1386 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.25 | ||||
Resistance 3 (R3) | 25.13 | 24.55 | 25.02 | ||
Resistance 2 (R2) | 24.55 | 24.21 | 24.61 | 24.94 | |
Resistance 1 (R1) | 24.22 | 23.99 | 24.39 | 24.34 | 24.87 |
Pivot Point | 23.64 | 23.64 | 23.73 | 23.70 | 23.64 |
Support 1 (S1) | 23.31 | 23.30 | 23.48 | 23.43 | 22.89 |
Support 2 (S2) | 22.73 | 23.08 | 22.79 | 22.82 | |
Support 3 (S3) | 22.40 | 22.73 | 22.74 | ||
Support 4 (S4) | 22.52 |